Bristol Myers Squibb has a robust pipeline with plenty of active programs, and its outlook for the next decade remains strong ...

Deep-pocketed investors have adopted a bullish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or hold heading into 2026.

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

The healthcare industry has never been a great source of dividends -- that alone makes these companies exceptional.

Bristol-Myers Squibb Company is rated a Buy with solid rebound and robust free cash flow margins. Learn more about BMY stock ...

Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an ...

Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will sell ...

Bristol Myers Squibb (NYSE: BMY) is a big name in healthcare. And over the years, it has always found ways to grow and expand its business. But this hasn't been a good buy of late. It's not just this ...

With that, here are two dividend stocks to consider scooping up right now.

Bristol Myers Squibb (BMS) has yet to announce official presentation plans at the 44 th annual JP Morgan Healthcare Conference, although Karin Shanahan, EVP, chief supply chain and operations officer, ...